SCHEMBL2280423

SCHEMBL2280423

COc1cc(C)n(C)c(=O)c1C(=O)/C=C/c1cccc(C(=O)NCC(=O)O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
P4HB P07237 1/20 0.42
MAPT P10636 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HIF1A Q16665 2/20 0.41
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
KCNA3 P22001 1/20 0.41
ABCB1 P08183 4/20 0.41
BCHE P06276 1/20 0.40
TP53 P04637 1/20 0.40
CYP3A4 P08684 1/20 0.40
ATM Q13315 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280425 1.00 SMN1; SMN2 (0.42) SMN1; SMN2KDM4EALDH1A1HPGDP4HB
SCHEMBL2278778 0.93 MAPK1 (0.42) SMN1; SMN2KDM4EALDH1A1P4HBMAPT
SCHEMBL2278780 0.93 MAPK1 (0.42) SMN1; SMN2KDM4EALDH1A1P4HBMAPT
SCHEMBL2281395 0.90 ABCG2 (0.45) KDM4EALDH1A1MAPTNPSR1HIF1A
SCHEMBL2281403 0.90 ABCG2 (0.45) KDM4EALDH1A1MAPTNPSR1HIF1A
SCHEMBL2278482 0.89 KDM4E (0.43) KDM4EALDH1A1HPGDP4HBMAPT
SCHEMBL2277068 0.89 KDM4E (0.43) KDM4EALDH1A1P4HBMAPTNPSR1
SCHEMBL2277074 0.89 KDM4E (0.43) KDM4EALDH1A1P4HBMAPTNPSR1
SCHEMBL2278483 0.89 KDM4E (0.43) KDM4EALDH1A1HPGDP4HBMAPT
SCHEMBL2284349 0.88 NPC1 (0.42) P4HBMAPTNPSR1HIF1APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 SMN1; SMN2 3766/4885KDM4E 2443/4885ALDH1A1 576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.